Mutations in the BARD1 gene were appreciated in 20–25% of tumor samples taken from the pancreas and the adrenal gland; however, the cohorts were very small and may not reflect the true prevalence of BARD1 mutations in pancreatic cancer and NB. This evidence concerns the gene BARD1 and neoplasm.